About us
SynapCon(c) develops advanced technologies and business models with a clear focus on accelerating the clinical development of drugs and medical devices, making products available to patients more quickly and reducing the burden on healthcare systems in the long term.
Following the founding idea of SynapCon, we focused on the development and marketing of outstanding IT solutions.
Our products are developed in collaboration with excellent development teams and specialists.
In close cooperation with our customers and many other market players, we are working to realize our common vision of providing optimal and affordable medical care worldwide.
Early Bird - Contact us now to receive special conditions (sales(at)synapcon.com)!
electronic TMF for the best price / performance ratio
Shorten your clinical research processes by using our CTMS system EasyClin(c), the eTMF will convince you and the optional eISF will inspire your study centers. Sign up for a demonstration today (sales(at)synapcon.com).
Need your customized enterprise solution? - contact us today (sales(at)synapcon.com)!
Clinical Research proven GDPR conform Videoconferencing platform
Reduce the number of on-site visits and meetings in your clinical research studies.
For more information and registration for free, follow this link: https://synapcon.com/study-site-selection/
Get the best from your clinical research network
The Clinical Trial Feasibility study evaluates the possibility of conducting a particular clinical program / trial in a particular geographical region with the overall objective of optimum project completion in terms of study site competencies, patient population, timelines, targets and cost.
Only the harmonious interaction of professional expertise combined with outstanding skills in technical development creates the prerequisites for creating complex architectures.
Our vision
A digital health approach that makes a difference for all stakeholders (including patients, doctors & payers) by IT powered management of drug and medical device development. It is our vision to innovate the clinical trials world through disrupting outdated processes and organizational structures.
Our innovative solutions optimize the interfaces between patient data, clinics and the industry that develops drugs and medical devices.
This includes the implementation of our digital solutions and coordinated consulting to optimize your processes.
You benefit from our market knowledge of the entire medical value chain.
Our goal is to provide our customers with profitable advantages from the current challenges of the market.
Our commitment and technical expertise helps shorten development cycles to ensure faster patient care and reduce development costs to make innovative medicines affordable.
Target Market
Diagnostics & medical device companies
Pharmaceutical companies
Biotechnology companies
Target Market
Institutions, patient organizations, charities and researching hospitals
Diagnostics & medical device companies
Pharmaceutical companies
Biotechnology companies
Service Providers
A digital health approach that makes a difference for all stakeholders (including patients, doctors & payers) by IT powered management of drug and medical device development. It is our vision to innovate the clinical trials world through disrupting outdated processes and organizational structures.
Change the game – use software solutions to perform clinical research projects more efficiently then ever before.
Our business model combines innovative IT product solutions and related consultancy support implemented by a lean organization built of IT-affine, curious, entrepreneurial, self responsible people & supported by our competitive FIDAS strategy.
Competitive Advantage
Our unique approach of Rethinking Clinical Research Operations
Focused│Integrated│Digitised│Automatised│Specialised (FIDAS)
Our proprietary IT systems: EasyClin© & CLiNSTORM©
Use our EU-GDPR compliant videoconferencing system to reduce the number of patient visits in your clinical research projects
Competitive Advantage
Our unique approach of Rethinking Clinical Research Operations
Focused│Integrated│Digitised
Automatised│Specialised (FIDAS)
Our proprietary IT systems: EasyClin© & CLiNSTORM© (artificial intelligence based solution in development )
Our enterprises
SynapCon Group develops new ways to set standards in clinical research through digital transformation.
We provide consultancy practice within the health market, investors and business arena
Success is at the heart of every project. We are committed to being a pillar of your success at all levels. Our unique approach is to rethink the Clinical Research approach by combining the latest IT solutions with clinical operations services to improve the value chains. This hybrid model ultimately forms the SynapCon Group’s innovative approach called CROIT (Clinical Research Operations Information Technology).
We help companies evolve within the complex healthcare environment. Our team of professionals supports companies in their development from a clinical, financial and entrepreneurial point of view.
Cutting-edge solutions through new thinking
We are optimizing interfaces between patient data, clinics and industry developing drugs and medical devices. Our mission is to implement a structure, based on a novel organizational partner structure and digital technologies. Our goals are: to positively influence the medical value chain in the health market to generate benefits for the community, this means, shortening development cycles to ensure faster patient care and reducing development costs to make innovative medicine affordable.
Our unique approach of Rethinking Clinical Research Operations is to build IT systems to further increase innovation within the clinical research market.
Efficently manage clinical research studies
Our Software solutions reduce the number of platforms in clinical research and, consequently, the costs of validating interfaces, maintenance, support and training. Our software reduces the time to market and extends the patent-protected marketing of your products. We always keep our eyes on the patients, providing people with a faster access to life-saving medical products is our driving force and shapes our actions.
EasyClin© is a newly designed platform and cost-effective software solution for your clinical research projects. This system will be the core of your study communication.
The system is designed to cover all requirements from the strictest regulations in Europe (EU-GDPR), US (21CFR Part 11) and ICH-GCP E6 R2.
The EasyClin(c) project has received funding from the European Union’s Horizon 2020 research and Innovation programme under grant Agreement No 691546
EasyClin© provides an integrated and regulatory compliant platform to effectively and efficiently manage clinical research studies.
Together with our partner AIFINITY Holding Ltd., we are developing the CLiNSTORM© system, using state-of-the-art technologies sustainably changing the expensive way of performing clinical research studies.
The first module is available serving our page visitors with the most current scientific information.
Information Centre
The CLiNSTORM© solution through its AI capabilities addresses central Clinical Research challenges
EasyVideo is a GDPR compliant peer-to-peer videoconferencing tool.
It is a safe and multilanguage tool supporting the communication between investigators and study subjects as well as between clinical monitors and investigators.
EasyVideo meets all requirements of GDPR, CCPA, 21 CFR Part 11 and is therefore safe to use in clinical studies.
The EasyVideo solution is ideal for use in demanding regulatory systems
We provide consultancy practice within the health market, finance and business arena
Success is at the heart of every project. We are committed to being a pillar of your success at all levels. Our unique approach is supporting our customers rethinking the Clinical Research approach by combining the latest IT solutions with clinical operations services to improve the value chains. This hybrid model ultimately forms the SynapCon Group’s innovative approach called CROIT (Clinical Research Operations Information Technology).
We help companies evolve within the complex healthcare environment. Our team of professionals supports companies in their development from a clinical, financial and entrepreneurial point of view.
Driving innovation through proprietary IT systems
We operate as a “Clinical Research Organization” (CRO) which optimizes interfaces between patient data, clinics and industry developing drugs and medical devices. Our mission is to implement a CRO 4.0, based on a novel organizational structure and digital technologies. Our goals are: taking profitable advantages out of current challenges in the CRO market to generate values, shortening development cycles to ensure faster patient care and reducing development costs to make innovative medicine affordable.
Our unique approach of Rethinking Clinical Research Operations (CROs) is to build IT systems to further increase innovation within the clinical research market.
Efficently manage clinical research studies
Our Software solutions reduce the number of platforms in clinical research and, consequently, the costs of validating interfaces, maintenance, support and training. Our software reduces the time to market and extends the patent-protected marketing of your products. We always keep our eyes on the patients, providing people with a faster access to life-saving medical products is a driving force and shapes our actions.
EasyClin© is a newly designed platform and cost-effective software solution for your clinical research projects. Following the successful release of our application to conduct clinical feasibility studies, we are pleased to welcome you to our Management System today. This system (and today it will gain access to the important area of document management) will in future be the core of your study communication. The type of access and availability are based on the social networks in the future. The authorization management fulfills the highest requirements also from the side of the regulators. Our three-way staggered hybrid model grows to meet your needs. Take care of the essentials, leave the rest to technology.
EasyClin provides an integrated and regulatory compliant platform to effectively and efficiently manage clinical research studies supported by the European Commission.
CLiNSTORM triples clinical research cost effciency and speed
CLiNSTORM©’s core business is delivering a smart and low cost cloud-client based solution for organizations to manage their clinical trials of medical devices, diagnostics and biopharmaceutics.
CLiNSTORM© is the brand of the organization as well as the name for the comprehensive solution offered. As the brand name suggests CLiNSTORM© will take the market by storm. This enabled by its revolutionary business model by being the first business within the clinical research industry that lets the customer pay by what they use; pay pro data point.
The CLiNSTORM© solution looks to meet the need of this target group of delivering a very scalable low cost solution.
Executive Team
Synapcon is managed by a highly experienced team, with offices throughout Europe and a global network of clients.
Sven Engel
CEO, CIO & Founder of SynapCon Ltd.
Biotechnologist, Clinical Researcher, 20 years of entrepreneurial experience, deep insight in the whole value chain of bio-pharmaceutical and medical product development, organisation and software developer, visionary and strategic thinking with the power to translate knowledge and information into products.
Holger Fuhrmann
HR Manager SynapCon Group
Head Talent Acquisition & Development, MBA (International Marketing) & Business Coach (DBVC), 17 years experience in the search, selection and development of specialist and executive staff in the life science industry, Founder and CEO of PHARECON (executive search company with life science focus in Europe).
Seko Williams
COO of SynapCon Ltd.
Entrepreneur, Economist, Physical Therapist, +10 years entrepreneurial experience, +9 years of experience in health care and physical training optimisation. Active project management & lean software development, for videoconferencing and calendar tools in digital healthcare. Developer of the first and only independently audited B2C videoconferencing platform for doctors & physician in Germany, in accordance with GDPR standards and federal medical association videoconferencing conditions.
Joachim Löw
CFO and co-founder of SynapCon Ltd., founder of Schulz&Löw Consulting
Business economist, controller and IT specialist with extensive experience in the implementation and development of business management software. Joachim works as an interim financial manager for a listed US company.
NEWS
Medical Device Regulation (EU MDR)
Initially the new MDR was scheduled to come in force on 26 May 2020. The transition period was extended due to the Covid-19 pandemic. It will now come into force in May 2021. There will not be another transitional period.
As a response manufacturer of medical devices for sale within the EU must adhere to strict guidelines to ensure their products are safe to use. This change will make clinical trials a necessity for many manufacturers.
That´s where we help. Our technology enables SMEs in the medical device sector to anticipate the technology of the “big players” at an unparalleled price-performance ratio. Find out more on how we can help your business get through these changes successfully by contacting sales@synapcon.com.
EasyFeasibility© available for free registration
Our product EasyFeasibility© (https://www.synapcon.com/study-site-selection) is available globally. Hundreds of sponsors, study sites and investigators can vouch for the high value of using platform-based feasibility solutions. Registration on EasyFeasibility© is free for sponsors, study sites and investigators.
New EasyTMF© released
SynapCon launches the next generation of its completely redesigned Clinical Trial Management System EasyClin©. The long-awaited re-release of EasyClin© is finally here and offers updated functionalities in EasyTMF©, our GDPR compliant electronic Trial Master File.
Distribution Partners wanted
SynapCon is looking to further expand its partner network within the European market. We offer above average commissions for sales professional and distributors. To find out more please contact our team at sales@synapcon.com.
Currently we are looking for sales partners in France, Italy, Spain, Belgium, and the Netherlands.
Investment Opportunities
SynapCon’s´ revolutionary approach to efficient software solutions for clinical trial management to enable faster drug development is capturing the attention of investors worldwide.
Speak to us today about the opportunities available.
Site Feasibility and Clinical Trial Management
Our feasibility platform radically simplifies feasibility studies, by simplifying the process of site selection for sponsors, contract research organization, investigators, and study sites.
Our Clinical Trial Management software systems (CTMS) design, based on more than 20 years´ of experience in client trials, provides our clients with the peace of mind that their clinical trial will be fulfilled quickly and efficiently, conform with EU-GDPR (General Data Protection Regulation) and ICH GCP (Good Clinical Practice).
Our newest developments will implement AI-assistance for site feasibility and clinical trial management.
Expert management
Our senior management team has more than 30 years’ experience in software development as well as practical experience in clinical trial management and drug development.
Explosive Demand
Software solutions in clinical trial management and drug development are one of the world’s fastest-growing industries, with demand set to grow at a CAGR of 13% until 2025.
Global Expansion
Our client network spans from North America, Europe, to Japan and we are actively expanding to more locations around the world.
Who we are looking for
Ideally, you are already invested in the medical field and have the expertise to make an appropriate investment decision. Your organization possesses a broad network in life sciences, ideally in clinical trials and pharma.
You have sufficient capital to support a project of this size over several funding rounds. You actively support us in the search for further investors to accelerate the global expansion of our business.
We kindly ask business angels to refrain from contacting us.
